Categories
Change Password!
Reset Password!
Remdesivir showed faster recovery and better survival rates in COVID-19
patients as compared to placebo.
As per
Dr Anthony Fauci, director of the National Institute of Allergy and Infectious
Diseases (NIAID) the U.S. government trial on remdesivir safety and efficacy
has shown a recovery rate 31% faster as compared to placebo, these are
preliminary trial results and are highly significant. The experimental drug by
Gilead Sciences Inc. (GILD.O) could become the standard of care for COVID-19
said, Dr Fauci. The FDA needs to be completely sure on the safety and efficacy
of the drug even before granting emergency authorization. Out of 1,063 COVID-19
patients, the remdesivir group recovered in 11 days and placebo group required
15 days to recover. The patients in remdesivir showed a better survival rate
than in the placebo group. The complete trial results are expected to be out by
mid-May. Dr Aneesh Mehta, a researcher on the NIH trial from Emory University
School of Medicine in Atlanta said that complete data will better clarify the
outcomes.
Reuters
Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'
Comments (0)